安进(Amgen)认罪,在7.62亿美元的“虚假索赔法”案中起诉中情局
安进“marketed the spread” between the price practices pay for Aranesp 和 that patients pay as a means of driving sales—to the point of having speakers tell docs that they could make a million more each year by prescribing the 安进anemia drug over its competitor, Procrit.